The relative expression level of the glycoform family L3 of AFP, which is mainly composed of core-fucosylated glycans, has been proven to be a malignant tumor-specific biomarker59 and is approved as a disease marker by the Food and Drug Administration (FDA) for early diagnosis of liver cancer.60 Currently existing analytical tools for the determination of the relative AFP-L3 level mainly rely on the use of antibodies and lectins.61 Due to their drawbacks as stated above, the precision of these assays remains not very high. This evidence concerns the gene AFP and liver cancer.